Q-omics provides the consensus-scored SLC16A13 profile across patient tissues and cancer cell-line models. SLC16A13 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SLC16A13 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, SLC16A13 RNA expression shows 18,843 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, KICH, and ACC as cancer lineages where SLC16A13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC16A13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC16A13 survival associations across molecular data types. SLC16A13 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC16A13 RNA expression–survival associations across cancer types. High SLC16A13 expression shows unfavorable associations in LUAD, MESO, ACC and KICH, but favorable associations in KIRC and SCLC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for SLC16A13 RNA expression.
This table summarizes SLC16A13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SLC16A13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC16A13 shows lower tumor expression in KICH and THCA and higher tumor expression in BLCA, COAD, STAD and BRCA. The KICH box plot shows higher SLC16A13 RNA expression in normal versus tumor tissue (log2 FC = −2.207, t-test p < 0.001).
This table shows molecular features associated with SLC16A13 in patient tissues and cancer cell lines. In patient samples, SLC16A13 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC16A13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
